Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNASDAQ:IRMDNASDAQ:SIBNNASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$19.24+0.8%$13.92$8.89▼$24.50$834.17MN/A495,122 shs82,664 shsIRMDIradimed$58.67+0.9%$54.01$42.11▼$63.29$745.99M0.9242,879 shs16,354 shsSIBNSI-BONE$17.75+1.9%$16.59$11.70▼$20.05$756.42M0.94423,519 shs82,909 shsTLSITriSalus Life Sciences$5.33+2.7%$5.40$3.50▼$6.14$201.68M0.4742,541 shs5,390 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+0.05%+32.94%+14.93%+1,908,999,900.00%IRMDIradimed0.00%-3.85%+7.90%+11.65%+34.50%SIBNSI-BONE0.00%-7.83%-11.98%+14.45%+37.60%TLSITriSalus Life Sciences0.00%-3.71%+0.97%+0.78%-10.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/AIRMDIradimed4.508 of 5 stars2.52.02.54.42.23.31.9SIBNSI-BONE4.0608 of 5 stars3.52.00.03.32.92.50.6TLSITriSalus Life Sciences3.6162 of 5 stars3.65.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.75Moderate Buy$23.4421.85% UpsideIRMDIradimed 3.00Buy$72.0022.72% UpsideSIBNSI-BONE 3.00Buy$22.5026.76% UpsideTLSITriSalus Life Sciences 3.25Buy$10.75101.69% UpsideCurrent Analyst Ratings BreakdownLatest TLSI, BBNX, SIBN, and IRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/6/2025SIBNSI-BONETruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSI-BONECantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/28/2025TLSITriSalus Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$69.83M11.95N/AN/AN/A∞IRMDIradimed$75.15M9.93$1.46 per share40.12$5.66 per share10.37SIBNSI-BONE$176.60M4.28N/AN/A$4.18 per share4.25TLSITriSalus Life Sciences$32.14M6.27N/AN/A($0.98) per share-5.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta BionicsN/AN/A0.00∞N/AN/AN/AN/AN/AIRMDIradimed$19.23M$1.5539.1129.34N/A26.26%24.12%21.20%7/30/2025 (Estimated)SIBNSI-BONE-$43.34M-$0.64N/AN/AN/A-23.82%-22.51%-16.53%8/4/2025 (Estimated)TLSITriSalus Life Sciences-$59.04M-$1.12N/AN/AN/A-206.24%N/A-236.83%8/13/2025 (Estimated)Latest TLSI, BBNX, SIBN, and IRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A5/5/2025Q1 2025SIBNSI-BONE-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million3/27/2025Q4 2024TLSITriSalus Life Sciences-$0.35-$0.35N/A-$0.40$8.12 million$8.26 million3/25/2025Q4 2024BBNXBeta Bionics-$0.42-$1.82-$1.40-$2.72$20.01 million$20.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AIRMDIradimed$0.681.16%N/A43.87%1 YearsSIBNSI-BONEN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ALatest TLSI, BBNX, SIBN, and IRMD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/AN/AN/AIRMDIradimedN/A9.217.82SIBNSI-BONE0.228.257.22TLSITriSalus Life SciencesN/A2.402.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AIRMDIradimed92.34%SIBNSI-BONE98.11%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AIRMDIradimed36.80%SIBNSI-BONE4.00%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/AIRMDIradimed11012.72 million7.97 millionOptionableSIBNSI-BONE35042.62 million40.30 millionOptionableTLSITriSalus Life Sciences10637.84 million20.49 millionNot OptionableTLSI, BBNX, SIBN, and IRMD HeadlinesRecent News About These CompaniesTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 70.0% in MayJune 13 at 9:34 AM | marketbeat.comResearch Analysts Set Expectations for TLSI FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Forecasts TLSI FY2026 EarningsJune 10, 2025 | marketbeat.comBank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)June 8, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Recommendation of "Buy" by BrokeragesJune 8, 2025 | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Buy" by BrokeragesJune 8, 2025 | marketbeat.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Growth in Short InterestMay 30, 2025 | marketbeat.comRoth Capital Issues Pessimistic Forecast for TLSI EarningsMay 25, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for TLSI EarningsMay 23, 2025 | marketbeat.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by BrokeragesMay 16, 2025 | marketbeat.comTriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSI, BBNX, SIBN, and IRMD Company DescriptionsBeta Bionics NASDAQ:BBNX$19.24 +0.15 (+0.79%) As of 11:56 AM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Iradimed NASDAQ:IRMD$58.67 +0.50 (+0.86%) As of 12:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.SI-BONE NASDAQ:SIBN$17.75 +0.33 (+1.89%) As of 12:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.TriSalus Life Sciences NASDAQ:TLSI$5.42 +0.23 (+4.34%) As of 12:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
